Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS) "XMAS"


Phase 4 Results N/A

Summary of Purpose

The main purpose of this trial is to determine whether Xingnaojing, intravenously administered within 24 hours of symptom onset, improves the 3-month outcome in participants with acute ischemic stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 31 October 2017.

1 Mar 2016 28 Mar 2016 1 Jan 2018 1 Jan 2018 1 Sep 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Single Blind (Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment